#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating children with drug-resistant epilepsy need awareness that medical cannabis remains inaccessible through NHS channels despite legal availability, creating a treatment gap for patients who have exhausted conventional anticonvulsant options. This advocacy campaign highlights the disconnect between policy change and clinical implementation, directly affecting prescribing decisions and patient outcomes for a vulnerable pediatric population. Understanding these access barriers helps clinicians better counsel families about realistic treatment options and advocate for systemic changes that could expand available therapeutic tools.
A campaign has been launched in the United Kingdom to address persistent barriers to NHS access for medical cannabis in pediatric drug-resistant epilepsy, a condition where the evidence base for cannabinoid therapy is strongest and clinical need is most acute. Despite legal changes that permitted physician prescribing of cannabis-based medicinal products in 2018, access remains severely restricted due to funding limitations, prescribing hesitancy, and lack of integrated pathways within the NHS system. The campaign highlights the gap between legal availability and practical patient access, particularly affecting families who either cannot afford private prescriptions or must pursue treatment outside conventional healthcare channels. Drug-resistant epilepsy in children represents a compelling clinical indication where cannabidiol has demonstrated efficacy in reducing seizures, yet many eligible young patients remain unable to access this therapy through their NHS providers. Clinicians in the UK managing pediatric epilepsy should be aware that advocacy efforts continue to expand patient access and that private pathways may be necessary until NHS provision improves. Physicians should counsel families with drug-resistant epilepsy about the regulatory status and access options available in their region, while supporting policy efforts that would integrate evidence-based cannabinoid therapy into standard NHS care pathways.
“We’ve known for nearly a decade that cannabidiol can be genuinely life-changing for certain pediatric seizure disorders like Dravet syndrome, yet access remains gatekept by politics rather than pharmacology. When families have to fight this hard just to get their children considered for a medication with solid evidence behind it, we’re failing our most vulnerable patients and extending unnecessary suffering.”
💊 While the regulatory pathway for cannabis-based medicinal products in the UK has expanded, significant barriers persist in translating policy changes into clinical access for patients with intractable epilepsy. The campaign highlights a genuine unmet need, particularly for pediatric cases where conventional anticonvulsants have failed and evidence for cannabis-derived cannabinoids (such as cannabidiol) shows promise in randomized trials. However, clinicians should recognize that access restrictions reflect not only funding constraints but also legitimate concerns about long-term safety data in developing brains, variability in product formulations, and the challenge of conducting robust comparative effectiveness research in this population. The gap between regulatory approval and NHS reimbursement underscores how policy, economics, and clinical evidence can diverge, leaving families to navigate private prescribing pathways when conventional options are exhausted. When counseling families facing drug-resistant pediatric epilepsy, practitioners should remain informed about current
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: